Osaka, May 8, 2008 (Jiji Press) - Dainippon Sumitomo Pharma Co. <4506> said Thursday it will start clinical development of a therapeutic agent for allergic disorders in collaboration with AstraZeneca PLC.
Through joint researches since 2004, the Japanese and British companies have discovered a chemical compound which can act as an immune response modifier that is effective against bronchial asthma and allergic rhinitis.
If the drug is successfully developed, Dainippon Sumitomo will sell the product in Japan, China, South Korea and Taiwan, while AstraZeneca will cover the rest of the world.
Dainippon Sumitomo will receive royalties for sales in the United States and some European countries.
The market for bronchial asthma drugs is estimated at 200 billion yen for Japan and 2 trillion yen for the world. The market for allergic rhinitis drugs is seen at 100 billion yen for Japan and 1.6 trillion yen for the world.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore
(Jan 22, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent
(Dec 28, 2012)
|
|
|
NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area
(Oct 23, 2008)
|
|
|
Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug
(May 8, 2008)
|
|
|
Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic
(Dec 13, 2006)
|
|
|
Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent
(Nov 28, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'
(Sept 21, 2006)
|
|
|
Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs
(July 26, 2006)
|
|
|
Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection
(June 16, 2006)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Drugs & OTC news...
|
|
)
